Health  Vol.4 No.11 A , November 2012
Pharmacological evaluation of catalepsy in low calcium and/or magnesium deficient feeding mice
Abstract: Populations from the Kii peninsula of Japan and Guam present a high incidence of amyotrophic lateral sclerosis and parkinsonism-dementia complex. It is thought that the low levels of calcium (Ca) and magnesium (Mg) in the drinking water are involved in the pathogenesis of these diseases. The present study aimed to test the hypothesis that catalepsy, a behavioral immobility and one of the Parkinsonian symptoms, may result from functionally impaired dopaminergic neurons in low Ca and Mg (LCa/Mg) fed mice. A group of mice fed with an LCa/Mg diet for 6 weeks was compared to a control group on a standard diet. Cataleptic symptoms such as akinesia and rigidity were measured using the bar test. The antiparkinsonian drugs dopamine (DA) precursor L-3, 4-dihydroxy phenylamine (L-DOPA), the selective DA receptor D2 agonist bromocriptine and the DA releaser amantadine were tested for their effects on the induced catalepsy. Mice developped catalepsy after 3 weeks on the LCa/Mg diet. LCa/Mg diet-induced catalepsy was improved by the administration of either L-DOPA (50 - 200 mg/kg i.p.) in combination with benserazide (25 mg/kg i.p.), bromo- criptine (0.25 - 4 mg/kg i.p.) or amantadine (5 - 20 mg/kg i.p.). These results suggest that catalepsy in LCa/Mg mice might result from a hypofunction of dopaminergic neurons. Moreover, our results support the hypothesis that LCa/Mg in-take may be one etiological factor in neurodegenerative disorders including Parkinson’s disease.
Cite this paper: Nakagawasai, O. , Taniguchi, R. , Tan-No, K. , Yamadera, F. , Nemoto, W. , Yaoita, F. and Tadano, T. (2012) Pharmacological evaluation of catalepsy in low calcium and/or magnesium deficient feeding mice. Health, 4, 1138-1144. doi: 10.4236/health.2012.431172.

[1]   Olanow, C.W. and Arendash, G.W. (1994) Metals and free radicals in neurodegeneration. Current Opinion in Neurology, 7, 548-558. doi:10.1097/00019052-199412000-00013

[2]   Yasui, M., Kihira, T. and Ota, K. (1992) Calcium, magnesium and alumi-num concentrations in Parkinson’s disease. Neurotoxicology, 13, 593-600.

[3]   Durlach, J., Bac, P., Durlach, V., Durlach, A., Bara, M. and Guiet-Bara, A. (1997) Are age-related neuro-degenerative diseases linked with various types of magnesium depletion? Magnesium Research, 10, 339-353.

[4]   Purdey, M. (2004) Elevated levels of ferrimagnetic metals in food chains supporting the Guam cluster of neurodegeneration: Do metal nucleated crystal contaminants [corrected] evoke magnetic fields that initiate the progressive pathogenesis of neurodegeneration? Medical Hypotheses, 63, 793-809. doi:10.1016/j.mehy.2004.04.029.

[5]   Yasui, M., Ota, K. and Garruto, R.M. (1995) Effects of calcium-deficient diets on manganese deposition in the central nervous system and bones of rats. Neurotoxicology, 16, 511-517.

[6]   Oyanagi, K., Ka-wakami, E., Kikuchi-Horie, K., Ohara, K., Ogata, K., Takahama, S., Wada, M., Kihira, T. and Yasui, M. (2006) Magnesium deficiency over generations in rats with special references to the pathogenesis of the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Neuropathology, 26, 115-128. doi:10.1111/j.1440-1789.2006.00672.x

[7]   Iseri, L.T. and French, J.H. (1984) Magnesium: Nature’s physiologic calcium blocker. American Heart Journal, 108, 188-193. doi:10.1016/0002-8703(84)90572-6

[8]   Ross, R.T. (1990) Drug-induced parkinsonism and other movement disorders. The Canadian Journal of Neurological Sciences, 17, 155-162.

[9]   Schmidt, W.J. and Kretschmer, B.D. (1997) Behavioural pharmacology of glutamate receptors in the basal ganglia. Neuroscience and Biobehavioral Reviews, 21, 381-392. doi:10.1016/S0149-7634(96)00044-9

[10]   Iuvone, P.M. (1984) Calcium, ATP, and magnesium activate soluble tyrosine hy-droxylase from rat striatum. Journal of Neurochemistry, 43, 1359-1368. doi:10.1111/j.1471-4159.1984.tb05395.x

[11]   Hashimoto, T., Nishi, K., Nagasao, J., Tsuji, S. and Oyanagi, K. (2008) Mag-nesium exerts both preventive and ameliorating effects in an in vitro rat Parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons. Brain Research, 1197, 143-151. doi:10.1016/j.brainres.2007.12.033

[12]   Nakamura, K., Bindokas, V.P., Marks, J.D., Wright, D.A., Frim, D.M., Miller, R.J. and Kang, U.J. (2000) The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: The role of mitochondrial complex I and reactive oxygen species revisited. Molecular Pharmacology, 58, 271-278.

[13]   Yasui, M., Yano, I., Yase, Y. and Ota, K. (1991) Distribution of calcium in central nervous system tissue and bones of maintained on calcium-deficient diets. Journal of the Neurological Sciences, 105, 206-210. doi:10.1016/0022-510X(91)90146-X

[14]   Garruto, R.M., Shankar, S.K., Yanagihara, R., Salazar, A.M., Amyx, H.L. and Gajdusek, D.C. (1989) Low-calcium, high-aluminum diet-induced motor neuron pathology in cynomolgus monkeys. Acta Neuropathologica, 78, 210-219. doi:10.1007/BF00688211

[15]   Strong, M.J. (1996) Modeling of acute and chronic aluminum neurotoxicity. In: Yasui, M., Strong, M.J., Ota, K. and Verity, M.A., Eds., Mineral and Metal Neurotoxicology, CRC Press, Boca Raton, 99-106.

[16]   Komatsu, F., Kagawa, Y., Kawabata, T., Kaneko, Y., Chimedregzen, U., Purvee, B. and Otgon, J. (2011) A high accumulation of hair minerals in Mongolian people: 2(nd) report; influence of manganese, iron, lead, cadmium and aluminum to oxidative stress, Parkinsonism and arthritis. Current Aging Science, 4, 42-56. doi:10.2174/1874609811104010042

[17]   Mena, I., Marin, O., Fuenzalida, S. and Cotzias, G.C. (1967) Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology, 17, 128-136. doi:10.1212/WNL.17.2.128

[18]   Pentschew, A., Ebner, F.F. and Kovatch, R.M. (1963) Experimental manganese encepha-lopathy in monkeys. A preliminary report. Journal of Neuropathology & Experimental Neurology, 22, 488-499. doi:10.1097/00005072-196307000-00010

[19]   Mustafa, S.J. and Chandra, S.V. (1971) Levels of 5-hy- droxytryptamine, dopamine and norepinephrine in whole brain of rabbits in chronic manganese toxicity. Journal of Neurochemistry, 18, 931-933. doi:10.1111/j.1471-4159.1971.tb12022.x

[20]   Neff, N.H., Barrett, R.E. and Costa, E. (1969) Selective depletion of caudate nucleus dopamine and serotonin during chronic manganese dioxide administration to squirrel monkeys. Cellular and Molecular Life Sciences, 25, 1140-1141. doi:10.1007/BF01900234

[21]   Cotzias, G.C., Papavasiliou, P.S., Ginos, J., Steck, A. and Düby, S. (1971) Metabolic modification of Parkinson’s disease and of chronic manganese poisoning. Annual Review of Medicine, 22, 305-326. doi:10.1146/

[22]   Verity, M.A. (1999) Manganese neurotoxicity: A mecha- nistic hypothesis. Neurotoxicology, 20, 489-497.

[23]   Nowak, P., Bojanek, K., Szkilnik, R., Jo?ko, J., Boroń, D., Adwent, M., Gorczyca, P., Kostrzewa, R.M. and Brus, R. (2011) Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. Neuro-toxicity Research, 19, 536-543. doi:10.1007/s12640-010-9184-0

[24]   Mayer, M.L., Westbrook, G.L. and Guthrie, P.B. (1984) Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature, 309, 261-263. doi:10.1038/309261a0

[25]   Schrattenholz, A. and Soskic, V. (2006) NMDA receptors are not alone: Dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to dis-ease-specific nuances of glutamate-signalling. Current Topics in Medicinal Chemistry, 6, 663-686. doi:10.2174/156802606776894519

[26]   Lin, J.Y., Chung, S.Y., Lin, M.C. and Cheng, F.C. (2002) Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Science, 71, 803-811. doi:10.1016/S0024-3205(02)01738-1

[27]   Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. and Prochiantz, A. (1984) Magnesium gates glutamate-activated channels in mouse central neurons. Nature, 307, 462-465. doi:10.1038/307462a0

[28]   Elliott, P.J., Close, S.P., Walsh, D.M., Hayes, A.G. and Marriott, A.S. (1990) Neuroleptic-induced catalepsy as a model of Parkinson’s disease. II. Effect of glutamate an- tagonists. Journal of Neural Transmission: Parkinson’s Disease and Dementia Section, 2, 91-100. doi:10.1007/BF02260897

[29]   Mele, A., Thomas, D.N. and Pert, A. (1997) Different neural mechanisms underlie dizocilpine maleate- and do- pamine agonist-induced locomotor activity. Neuroscience, 82, 43-58. doi:10.1016/S0306-4522(97)00277-7

[30]   Morelli, M., Fenu, S., Pinna, A. and Di Chiara, G. (1992) Opposite effects of NMDA and AMPA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. The Journal of Pharmacology and Experimental Therapeutics, 260, 402-408.

[31]   Ossowska, K. (1994) The role of excitatory amino acids in experimental models of Parkinson’s disease. Journal of Neural Transmission: Parkinson’s Disease and Dementia Section, 8, 39-71. doi:10.1007/BF02250917